News | June 02, 2021
Lasa Supergenerics FY21 profit up 521%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
India sales grew 23.5% YoY with consolidation of Wockhardt products
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Subscribe To Our Newsletter & Stay Updated
